239 related articles for article (PubMed ID: 28149332)
1. The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry.
Zhao H; Ning S; Nolley R; Scicinski J; Oronsky B; Knox SJ; Peehl DM
Clin Epigenetics; 2017; 9():4. PubMed ID: 28149332
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity.
Zhao H; Ning S; Scicinski J; Oronsky B; Knox SJ; Peehl DM
Oncotarget; 2015 Dec; 6(41):43172-81. PubMed ID: 26657731
[TBL] [Abstract][Full Text] [Related]
3. A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells.
Das DS; Ray A; Das A; Song Y; Tian Z; Oronsky B; Richardson P; Scicinski J; Chauhan D; Anderson KC
Leukemia; 2016 Nov; 30(11):2187-2197. PubMed ID: 27118403
[TBL] [Abstract][Full Text] [Related]
4. A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity?
Cabrales P; Scicinski J; Reid T; Kuypers F; Larkin S; Fens M; Oronsky A; Oronsky B
Med Oncol; 2016 Jul; 33(7):63. PubMed ID: 27229330
[TBL] [Abstract][Full Text] [Related]
5. RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors.
Oronsky B; Scicinski J; Cabrales P; Minchinton A
Clin Epigenetics; 2016; 8():53. PubMed ID: 27175220
[TBL] [Abstract][Full Text] [Related]
6. Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.
Reid T; Oronsky B; Scicinski J; Scribner CL; Knox SJ; Ning S; Peehl DM; Korn R; Stirn M; Carter CA; Oronsky A; Taylor MJ; Fitch WL; Cabrales P; Kim MM; Burris HA; Lao CD; Abrouk NED; Fanger GR; Infante JR
Lancet Oncol; 2015 Sep; 16(9):1133-1142. PubMed ID: 26296952
[TBL] [Abstract][Full Text] [Related]
7. RRx-001, a novel clinical-stage chemosensitizer, radiosensitizer, and immunosensitizer, inhibits glucose 6-phosphate dehydrogenase in human tumor cells.
Oronsky B; Scicinski J; Reid T; Oronsky A; Carter C; Oronsky N; Cabrales P
Discov Med; 2016 Apr; 21(116):251-65. PubMed ID: 27232511
[TBL] [Abstract][Full Text] [Related]
8. Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001.
Ning S; Sekar TV; Scicinski J; Oronsky B; Peehl DM; Knox SJ; Paulmurugan R
Oncotarget; 2015 Aug; 6(25):21547-56. PubMed ID: 26280276
[TBL] [Abstract][Full Text] [Related]
9. Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
Oronsky B; Guo X; Wang X; Cabrales P; Sher D; Cannizzo L; Wardle B; Abrouk N; Lybeck M; Caroen S; Oronsky A; Reid TR
J Med Chem; 2021 Jun; 64(11):7261-7271. PubMed ID: 34043360
[TBL] [Abstract][Full Text] [Related]
10. RRx-001 protects normal tissues but not tumors via Nrf2 induction and Bcl-2 inhibition.
Oronsky B; Scribner C; Aggarwal R; Cabrales P
J Cancer Res Clin Oncol; 2019 Aug; 145(8):2045-2050. PubMed ID: 31250159
[TBL] [Abstract][Full Text] [Related]
11. RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials.
Oronsky B; Paulmurugan R; Foygel K; Scicinski J; Knox SJ; Peehl D; Zhao H; Ning S; Cabrales P; Summers TA; Reid TR; Fitch WL; Kim MM; Trepel JB; Lee MJ; Kesari S; Abrouk ND; Day RM; Oronsky A; Ray CM; Carter CA
Expert Opin Investig Drugs; 2017 Jan; 26(1):109-119. PubMed ID: 27935336
[TBL] [Abstract][Full Text] [Related]
12. RRx-001 Increases Erythrocyte Preferential Adhesion to the Tumor Vasculature.
Jani VP; Asaro R; Oronsky B; Cabrales P
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946824
[TBL] [Abstract][Full Text] [Related]
13. Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: a superagonist of nitric oxide generation.
Fens MH; Cabrales P; Scicinski J; Larkin SK; Suh JH; Kuypers FA; Oronsky N; Lybeck M; Oronsky A; Oronsky B
Med Oncol; 2016 Aug; 33(8):85. PubMed ID: 27377482
[TBL] [Abstract][Full Text] [Related]
14. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation.
Reu FJ; Bae SI; Cherkassky L; Leaman DW; Lindner D; Beaulieu N; MacLeod AR; Borden EC
J Clin Oncol; 2006 Aug; 24(23):3771-9. PubMed ID: 16801630
[TBL] [Abstract][Full Text] [Related]
15. RRx-001, A novel dinitroazetidine radiosensitizer.
Oronsky B; Scicinski J; Ning S; Peehl D; Oronsky A; Cabrales P; Bednarski M; Knox S
Invest New Drugs; 2016 Jun; 34(3):371-7. PubMed ID: 26841903
[TBL] [Abstract][Full Text] [Related]
16. CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer.
Morra F; Merolla F; Criscuolo D; Insabato L; Giannella R; Ilardi G; Cerrato A; Visconti R; Staibano S; Celetti A
J Exp Clin Cancer Res; 2019 Feb; 38(1):90. PubMed ID: 30786932
[TBL] [Abstract][Full Text] [Related]
17. 5-Aza-cytidine is a potent inhibitor of DNA methyltransferase 3a and induces apoptosis in HCT-116 colon cancer cells via Gadd45- and p53-dependent mechanisms.
Schneider-Stock R; Diab-Assef M; Rohrbeck A; Foltzer-Jourdainne C; Boltze C; Hartig R; Schönfeld P; Roessner A; Gali-Muhtasib H
J Pharmacol Exp Ther; 2005 Feb; 312(2):525-36. PubMed ID: 15547111
[TBL] [Abstract][Full Text] [Related]
18. Platelet inhibitory effects of the Phase 3 anticancer and normal tissue cytoprotective agent, RRx-001.
Oronsky B; Oronsky N; Cabrales P
J Cell Mol Med; 2018 Oct; 22(10):5076-5082. PubMed ID: 30010241
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic effects of inhibition of heat shock protein 90 (HSP90) in human pancreatic and colon cancer.
Nagaraju GP; Wu C; Merchant N; Chen Z; Lesinski GB; El-Rayes BF
Cancer Lett; 2017 Aug; 402():110-116. PubMed ID: 28583846
[TBL] [Abstract][Full Text] [Related]
20. RRx-001 protects against cisplatin-induced toxicities.
Oronsky B; Reid TR; Larson C; Carter CA; Brzezniak CE; Oronsky A; Cabrales P
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1671-1677. PubMed ID: 28417195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
